PARIS Nov 3 Sanofi and BioNTech said they signed a collaboration and licence agreement to discover and develop up to five cancer immunotherapies, the companies said in a statement on Tuesday.
BioNTech will receive $60 million in upfront and near-term milestone payments and could receive over $300 million in development, regulatory and commercial milestones and other payments per product, the companies said.
22:33 Allergan to pay $15 million over failing to disclose merger talks17
21:40 HP Enterprise to buy cloud software company SimpliVity17
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
17:34 Boston Red Sox sign Jackie Bradley for $3.6 million15